Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Assets (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Current Assets for 5 consecutive years, with $276.6 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets rose 4.41% year-over-year to $276.6 million; the TTM value through Mar 2026 reached $276.6 million, up 4.41%, while the annual FY2025 figure was $229.0 million, 36.42% down from the prior year.
  • Current Assets hit $276.6 million in Q1 2026 for Phathom Pharmaceuticals, up from $229.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $397.4 million in Q4 2023 and bottomed at $139.8 million in Q1 2023.
  • Average Current Assets over 5 years is $253.6 million, with a median of $229.0 million recorded in 2025.
  • Year-over-year, Current Assets surged 147.6% in 2023 and then plummeted 44.42% in 2025.
  • Phathom Pharmaceuticals' Current Assets stood at $160.5 million in 2022, then skyrocketed by 147.6% to $397.4 million in 2023, then dropped by 9.38% to $360.1 million in 2024, then crashed by 36.42% to $229.0 million in 2025, then grew by 20.79% to $276.6 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $276.6 million, $229.0 million, and $207.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.